Keeping You Updated
Matrix Corporate Capital and PharmaVentures announce the signing of a Memorandum of Understanding (MOU)
London and Oxford, United Kingdom - March 15, 2010: Matrix Corporate Capital ('Matrix') and PharmaVentures Limited ('PharmaVentures') today announced the signing of a Memorandum of Understanding ('MOU') covering strategic transactions in the biotech, pharmaceutical and med tech sectors. The companies will work together to identify licensing, buyout, investment, IPO and consolidation opportunities which bring together both strategic expertise and capital from Europe's dedicated healthcare investors.
The MOU joins two firms with synergistic transactional capabilities in the healthcare life sciences space:
Matrix is a provider of a full range of corporate finance services to small and mid cap growth companies. They are able to service companies across the full corporate lifecycle, with access to financing from Series A venture finance through IPO, secondary placements and traded debt.
PharmaVentures is a leading specialist healthcare business advisory group assisting corporations in all aspects of strategic transactions, from strategy formulations to implementation. PharmaVentures has an extensive track record of successful strategic advisory mandates in the sector with over 17 years of experience and 450 assignments, for over 600 clients, in 38 countries.
Fintan Walton, Chief Executive of PharmaVentures said 'For our clients our alliance with Matrix will create one of Europe's strongest teams in healthcare transactions and equity financing. Our clients have always demanded the best and a strong experienced healthcare team is essential to their own success. Matrix has excellent proven capabilities in corporate finance and we are delighted to have entered into this agreement.'
Malcolm Le May, Chief Executive of Matrix Corporate Capital said 'We are delighted to team our skills with those of PharmaVentures. It has an excellent track record with some of the largest names in the pharmaceutical sector. Many of these companies now face unprecedented change in their business models, with the pursuit of greater efficiency driving buyouts; assets sales and licensing. Matrix has access to both private and public sector-specific capital across Europe which, with PharmaVentures' help, will allow us to create innovative transactions around these assets.'
Contact
Matrix Corporate Capital LLP
Steve Cox, Partner
+44 203 206 7000
PharmaVentures Limited
Tibor Papp
+44 (0)1865 332700
About Matrix Group
Matrix Corporate Capital is part of Matrix Group which is a privately owned financial services business founded in 1987 other areas of expertise include Asset Management, Property, and Specialised Finance. To date Matrix has raised around £8 billion for its investment products and currently has circa £3 billion of funds under management. Matrix's staff of over 200 are based in the West End of London at One Vine Street. Matrix Group Limited is the holding company for the following business activities.
- ends -
Note to Editors
PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevision produces the highly popular PharmaDeals® range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com).
Now in its 18th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.